COAGENTUS PHARMA, LLC announces its intention to create a $500 million fund, from known private Asian sources, to invest in biotechnology companies in U.S.

Share Article

Los Angeles-based global contract research and management consulting organization will use the funds to make strategic equity investments and/or acquisitions in biotech startups, growing companies, and publicly listed companies with promising opportunities in key health sectors, including cancer, cardiovascular medicine, diabetes and metabolic diseases, regenerative medicine, neurodegenerative diseases, personalized medicine, and clinical applications of gene editing

Dec 16, 2017, 04:00 ET

Los Angeles, December 16, 2017 /PR Web/--COAGENTUS PHARMA, LLC is a global contract research and management consulting organization serving clients within pharma, medical device and biotech sectors. COAGENTUS offers consultative R&D and regulatory services for pharmaceutical and biologic products, and medical devices that combine quality, speed, and value. COAGENTUS focuses on customer service, creating collaborations with our global partners that successfully advance their research and development strategies. COAGENTUS’ expertise in preclinical, CMC, bioanalytical, biologics, and clinical services ensures that programs are fully integrated from inception to regulatory submission, and are run smoothly with aggressive execution, on time and on budget.
Beyond CRO services, COAGENTUS provides startups, growing companies, and listed companies, with funding as a private investor, ranging from $ 5mm to $ 100mm.
COAGENTUS will be actively seeking strategic equity investment and/or acquisition opportunities as follows:

1.    Areas of business

a.    Cancer
b.    Cardiovascular Medicine
c.    Diabetes and Metabolic Diseases
d.    Regenerative Medicine
e.    Neurodegenerative Diseases
f.    Personalized Medicine
g.    Clinical Application of Gene Editing
h.    Other biotechnology applications

2.    Investment Amount

a.    $ 10mm to $ 30mm in private companies
b.    $ 10mm to $ 100mm in a publicly listed companies

3.    Investment Process

a.    Depending, and conditioned, upon satisfactory conclusion of due diligence and final approval by COAGENTUS’ Investment Committee, it normally takes 1-to-3 months from due diligence to final documentation.
b.    Interested potential investees are encouraged to contact COAGENTUS immediately.

Contact information:
Coagentus Pharma, LLC
6 Centerpointe Drive, #625
La Palma, CA 90623
Attn: Mr. Chris Kim, JD, LLM, SJD

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Kim
Visit website